2016 American Transplant Congress » Concurrent Session: Viral Hepatitis

2:30pm-2:42pm

Utilization and Discard of HCV+ Donor Livers in the Advent of Direct-Acting Antiviral Therapy.

M. Bowring, L. Kucirka, A. Massie, X. Luo, M. Sulkowski, D. Segev, C. Durand.

2:42pm-2:54pm

Hepatitis E Virus (HEV) Infection Among Kidney Transplant Patients in a Northeast US Center.

M. Lim,¹ S. Kamili,² T. Greene,² A. Tejada-Strop,² J. Drobeniuc,² M. Vanderveen,¹ R. Bloom.¹

2:54pm-3:06pm

An Economical and Effective Vaccination Program in Patients Transplanted for Hepatitis B Virus Related Liver Diseases: A Prospective Study.

W. Ju, A. Yang, Q. Ren, D. Wang, Z. Guo, Y. Ma, A. Hu, Q. Tai, X. Zhu, X. He.

3:06pm-3:18pm

High Efficacy of Ledipasvir/Sofosbuvir with Ribavirin in HCV Genotype-1 Infected Patients with Decompensated Liver Disease: Analysis by MELD Score from the SOLAR-1 and SOLAR-2 Trials.

M. Charlton,¹ E. Yoshida,² M. Bouliere,³ S. Flamm,⁴ A. Muir,⁵ M. Fried,⁶ N. Terrault,⁷ S. Arterburn,⁸ C. Yun,⁸ P. Pang,⁸ A. Osinusi,⁸ J. Spellman,⁸ M. Natha,⁸ D. Brainard,⁸ J. McHutchison,⁸ M. Manns,⁹ N. Afdhal.¹⁰

3:18pm-3:30pm

Time Course of Hepatic Graft Function Improvement After Ledipasivir/Sofosbuvir Treatment in Liver Transplant Recipients with HCV and Fibrosis or Cirrhosis Who Achieved SVR.

S. Helmke,¹ J. O'Leary,² J. Burton,¹ M. Cookson,¹ S. Lauriski,¹ J. Trotter,² J. McHutchison,³ G. Everson.¹

3:30pm-3:42pm

Decline of HCV RNA and Core Antigen: Predictors of Achieving SVR in Transplant Recipients Undergoing DAA-Therapy.

S. Pischke,³ V. Proske,¹ S. Polywka,⁴ M. Lütgehetmann,⁴ M. Lang,¹ S. Stauga,¹ L. Fischer,¹ A. Lohse,³ B. Nashan,² M. Sterneck.¹

3:42pm-3:54pm

Large Single-Center Experience of Sofosbuvir and Ledipasvir Therapy for the Treatment of Post-Liver Transplant Patients with Hepatitis C Virus.

J. Wedd, R. Ford, J. Norvell, S. Parekh, N. Cheng, N. Young, A. Patel, R. Maheshwari, R. Vora, O. Mgbemena, J. Spivey, A. Pillai.